0001558370-21-000067.txt : 20210107 0001558370-21-000067.hdr.sgml : 20210107 20210107070207 ACCESSION NUMBER: 0001558370-21-000067 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210107 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210107 DATE AS OF CHANGE: 20210107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kala Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001479419 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270604595 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38150 FILM NUMBER: 21512972 BUSINESS ADDRESS: STREET 1: 490 ARSENAL WAY STREET 2: SUITE 120 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 781-996-5252 MAIL ADDRESS: STREET 1: 490 ARSENAL WAY STREET 2: SUITE 120 CITY: WATERTOWN STATE: MA ZIP: 02472 8-K 1 kala-20210107x8k.htm 8-K
0001479419false00014794192021-01-072021-01-07

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2021

Kala Pharmaceuticals, Inc.

(Exact Name of Company as Specified in its Charter)

​

​

​

​

Delaware

001-38150

27-0604595

(State or Other Jurisdiction
of Incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

​

490 Arsenal Way, Suite 120

Watertown, MA 02472

(Address of Principal Executive Offices) (Zip Code)

Company’s telephone number, including area code: (781) 996-5252

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

​

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

​

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

​

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

​

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

​

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Global Select Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

​

​

​

Item 2.02.      Results of Operations and Financial Condition.

On January 7, 2021, Kala Pharmaceuticals, Inc. (the “Company”) issued a press release to announce the commercial launch of EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25%, its product for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. Although the Company has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2020, the Company disclosed in the press release that it expects to report cash, cash equivalents and short-term investments of approximately $153.5 million as of December 31, 2020. The estimated cash, cash equivalents and short-term investments figure includes net proceeds generated from the sale of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) under its “at-the-market” offering program during the fourth quarter of 2020. The press release is attached hereto as Exhibit 99.1.

The estimated cash, cash equivalents and short-term investments figure is preliminary and unaudited, represents management’s estimate as of the date of this report and is subject to completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the estimated cash, cash equivalents and short-term investments figure.

The information in this Item 2.02 is furnished under Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01.      Other Events.

Commercial Launch of EYSUVIS

On January 7, 2021, the Company issued a press release to announce the commercial launch of EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, its product for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. The information set forth in Item 2.02 of this Form 8-K regarding the Company’s estimated, preliminary cash, cash equivalents and short-term investments as of December 31, 2020 is incorporated by reference into this Item 8.01.

At-the-Market Offering Program Update

As previously reported, on May 7, 2020, the Company entered into an Amended and Restated Sales Agreement (the “Sales Agreement”) with Jefferies LLC (“Jefferies”), as agent, pursuant to which the Company may offer and sell shares of its Common Stock for aggregate gross sale proceeds of up to $75.0 million from time to time through Jefferies under an “at-the-market” offering program. During the fourth quarter of 2020, the Company issued and sold an aggregate of 2,821,059 shares of its Common Stock under its “at-the-market” offering program for aggregate net sale proceeds of approximately $20.6 million, after deducting sales commissions.

Cash Runway

The Company anticipates that its cash, cash equivalents and short-term investments as of December 31, 2020, along with anticipated sales of INVELTYS (loteprednol etabonate ophthalmic suspension) 1.0%, will enable it to fund its operations into at least the fourth quarter of 2022. The Company also expects revenue anticipated to be generated from sales of EYSUVIS will provide additional cash runway. The Company has based this estimate on assumptions that may prove to be wrong, and it could use its capital resources sooner than it currently expects.

Forward-Looking Statements

This Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the Company’s plan to grow its sales force to 125 sales representatives in 2021, pending the status of the COVID-19 pandemic; the status of insurance coverage and the availability of reimbursements for EYSUVIS and INVELTYS for commercial and Medicare Part D

patients; the commercial potential for EYSUVIS and INVELTYS; the Company’s plans to advance its preclinical pipeline of programs and the potential benefits of such programs; and the Company’s expectations regarding its use of cash, cash runway and projected revenues. All statements, other than statements of historical facts, contained in this Form 8-K, including statements regarding the Company’s strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of various risks and uncertainties including, but not limited to: the impact of extraordinary external events, such as the current pandemic health event resulting from the novel coronavirus (COVID-19), and their collateral consequences, including disruption of the activities of the Company’s sales force and the market for EYSUVIS and INVELTYS; whether the Company will be able to successfully implement its commercialization plans for EYSUVIS and INVELTYS; whether the market opportunity for EYSUVIS and INVELTYS is consistent with the Company’s expectations and market research; the Company’s ability execute on the commercial launch of EYSUVIS on the timeline expected, or at all, including obtaining Commercial and Medicare Part D payor coverage; whether the Company will be able to generate its projected net product revenue on the timeline expected, or at all; whether the Company's cash resources will be sufficient to fund the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements for the Company's expected timeline; other matters that could affect the availability or commercial potential of EYSUVIS and INVELTYS; and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K, most recently filed Quarterly Report on Form 10-Q and other filings the Company makes with the Securities and Exchange Commission. These forward-looking statements represent the Company’s views as of the date of this Form 8-K and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

​

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

​

99.1

Press Release of Kala Pharmaceuticals, Inc., dated January 7, 2021

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

 

KALA PHARMACEUTICALS, INC.

 

 

 

Date: January 7, 2021

By:

/s/ Eric L. Trachtenberg

 

 

Name: Eric L. Trachtenberg

 

 

Title: General Counsel, Chief Compliance Officer & Corporate Secretary

​

​

​

​

 EX-99.1 2 kala-20210107xex99d1.htm EX-99.1

Exhibit 99.1

Kala Pharmaceuticals Announces Availability of EYSUVISTM for the
Treatment of Dry Eye Disease and Provides Update on Development
Pipeline

-- First and only prescription therapy approved specifically for short-term treatment of the signs and symptoms of dry eye disease now available in pharmacies nationwide --

-- Advancing multiple NCE development programs targeted to address front and back of eye
diseases --

WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the launch of EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. EYSUVIS is now available in national and regional U.S. pharmaceutical distribution centers. Patients with a prescription can access EYSUVIS through their local retail pharmacies or through home delivery.

Kala has completed the hiring and onboarding of its expanded ophthalmology sales force, which now consists of 91 sales professionals calling on eyecare professionals, including ophthalmologists and optometrists. The Company plans to expand its sales force to approximately 125 sales representatives in 2021, pending the status of the COVID-19 pandemic. In addition, Kala’s payor account team is actively engaged in contract discussions with Commercial and Medicare Part D health plans.

“We are excited to announce our second product launch in two years, with EYSUVIS now available in the United States as the first approved prescription therapy specifically indicated for the short-term treatment of dry eye disease,” said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals. “We are looking forward to bringing this important new therapy to the millions of dry eye disease patients who suffer from episodic flares but did not have an FDA-approved rapid-acting, prescription treatment option prior to EYSUVIS. As we execute against our strategy to establish EYSUVIS as the preferred, first-line prescription therapy for dry eye disease, we continue to promote INVELTYS® as the first and only twice daily corticosteroid for post-operative inflammation and pain following ocular surgery, while also advancing Kala’s next wave of pre-clinical development programs in our pipeline.”

Kala is progressing its pipeline of pre-clinical development programs targeted to address front and back of the eye diseases. These programs, all of which are new chemical entities (NCEs), include: (1) a receptor Tyrosine Kinase Inhibitor program (rTKI), for the treatment of retinal diseases, including wet age-related macular degeneration (Wet AMD); (2) selective glucocorticoid receptor modulators (SEGRMs), which are a novel class of therapies designed to modify the downstream activity of the receptors to exhibit the anti-inflammatory and immunomodulatory properties of corticosteroids while potentially avoiding the typical safety concerns of steroids; and (3) novel steroids designed to target the ocular surface and thus have the potential to be a safer alternative to traditional topical steroids . Kala owns all intellectual property and worldwide rights to these pipeline candidates.

Although the Company has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2020, it expects to report cash, cash equivalents and short-term investments of approximately $153.5 million as of December 31, 2020. Preliminary cash, cash equivalents and short-term investments include net proceeds generated from the sale of shares of Common Stock under the Company’s “at-the-market” offering program during the fourth quarter of 2020. Kala anticipates that its cash, cash equivalents and short-term investments as of December 31, 2020, along with anticipated sales of INVELTYS, will enable it to fund its operations into at least the fourth quarter of 2022. Kala expects revenue anticipated to be generated from sales of EYSUVIS will provide additional cash runway.

​

About EYSUVIS

EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% is approved for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. EYSUVIS utilizes Kala's proprietary AMPPLIFY mucus-penetrating particle (MPP) Drug Delivery Technology to enhance penetration of loteprednol etabonate (LE) into target tissue of the ocular surface. EYSUVIS was approved by the FDA on October 26, 2020. Kala believes that EYSUVIS' broad mechanism of action, rapid onset of relief of both signs and symptoms, favorable tolerability and safety profile and the potential to be complementary to existing therapies, offer a differentiated product profile for the treatment of dry eye disease, including the management of dry eye flares.

EYSUVIS Important Safety Information

EYSUVIS, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. The initial prescription and each renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, as well as defects in visual acuity and fields of vision. Corticosteroids should be used with caution in the presence of glaucoma. Renewal of the medication order should be made by a physician only after examination of the patient and evaluation of the IOP. Use of corticosteroids may result in posterior subcapsular cataract formation. Use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, corticosteroids may mask infection or enhance existing infection. Use of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion must be considered in any persistent corneal ulceration where a corticosteroid has been used or is in use. The most common adverse drug reaction following the use of EYSUVIS for two weeks was instillation site pain, which was reported in 5% of patients.

Please see full Prescribing Information at www.eysuvis.com

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties, including statements regarding the Company’s plan to grow its sales force to 125 sales representatives in 2021, pending the status of the COVID-19 pandemic; the status of insurance coverage and the availability of reimbursements for EYSUVIS and INVELTYS for commercial and Medicare Part D patients; the commercial potential for EYSUVIS and INVELTYS; Kala’s plans to advance its preclinical pipeline of programs and the potential benefits of such programs; and the Company’s expectations regarding its use of cash, cash runway and projected revenues. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company’s strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of various risks and uncertainties including, but not limited to: the impact of extraordinary external

events, such as the current pandemic health event resulting from the novel coronavirus (COVID-19), and their collateral consequences, including disruption of the activities of the Company’s sales force and the market for EYSUVIS and INVELTYS; whether the Company will be able to successfully implement its commercialization plans for EYSUVIS and INVELTYS; whether the market opportunity for EYSUVIS and INVELTYS is consistent with the Company’s expectations and market research; the Company’s ability execute on the commercial launch of EYSUVIS on the timeline expected, or at all, including obtaining Commercial and Medicare Part D payor coverage; whether the Company will be able to generate its projected net product revenue on the timeline expected, or at all; whether the Company's cash resources will be sufficient to fund the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements for the Company's expected timeline; other matters that could affect the availability or commercial potential of EYSUVIS and INVELTYS; and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K, most recently filed Quarterly Report on Form 10-Q and other filings the Company makes with the Securities and Exchange Commission. These forward-looking statements represent the Company’s views as of the date of this release and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Investors:

Loraine Spreen

loraine.spreen@kalarx.com

857-277-4842

Hannah Deresiewicz

hannah.deresiewicz@sternir.com

212-362-1200

Source: Kala Pharmaceuticals, Inc.

Graphic

 GRAPHIC 3 kala-20210107xex99d1001.jpg GRAPHIC begin 644 kala-20210107xex99d1001.jpg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end EX-101.SCH 4 kala-20210107.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 kala-20210107_lab.xml EX-101.LAB EX-101.PRE 6 kala-20210107_pre.xml EX-101.PRE XML 7 kala-20210107x8k_htm.xml IDEA: XBRL DOCUMENT 0001479419 2021-01-07 2021-01-07 0001479419 false 8-K 2021-01-07 Kala Pharmaceuticals, Inc. DE 001-38150 27-0604595 490 Arsenal Way Suite 120 Watertown MA 02472 781 996-5252 false false false false Common Stock, $0.001 par value per share KALA NASDAQ true true XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information
Jan. 07, 2021
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Jan. 07, 2021
Entity File Number 001-38150
Entity Registrant Name Kala Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 27-0604595
Entity Address, Address Line One 490 Arsenal Way
Entity Address, Adress Line Two Suite 120
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code 781
Local Phone Number 996-5252
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol KALA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
Entity Central Index Key 0001479419
Amendment Flag false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.kalarx.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports kala-20210107x8k.htm kala-20210107.xsd kala-20210107_lab.xml kala-20210107_pre.xml kala-20210107xex99d1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "kala-20210107x8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "kala-20210107x8k.htm" ] }, "labelLink": { "local": [ "kala-20210107_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "kala-20210107_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "kala-20210107.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "kala", "nsuri": "http://www.kalarx.com/20210107", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "kala-20210107x8k.htm", "contextRef": "Duration_1_7_2021_To_1_7_2021_y1HhPivl4EOpq2GY3JHQLA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "kala-20210107x8k.htm", "contextRef": "Duration_1_7_2021_To_1_7_2021_y1HhPivl4EOpq2GY3JHQLA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Adress Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kalarx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001558370-21-000067-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-21-000067-xbrl.zip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end